Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04656652 · OUTCOME

Progression-free Survival (PFS) As Assessed by Investigator Per RECIST v1.1 Following DS-1062a Versus Docetaxel

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) · Source last updated 2026-08-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
From randomization until disease progression or death (whichever occurs first), up to approximately 43 months

What was measured

PFS is defined as the time from randomization to the earlier of the dates of the first documentation of radiographic progressive disease or death due to any cause.

Groups in this outcome

DS-1062a 6.0 mg/kg

Participants were randomized to receive 6.0 mg/kg of DS-1062a.

Docetaxel 75 mg/m^2

Participants were randomized to receive 75 mg/m\^2 docetaxel.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
DS-1062a 6.0 mg/kg299
Docetaxel 75 mg/m^2305

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
DS-1062a 6.0 mg/kg4.4Not reported4.25.5Not reported
Docetaxel 75 mg/m^23.0Not reported2.84.0Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        4.2
        upper Limit
        5.5
        value
        4.4
      2. group Id
        OG001
        lower Limit
        2.8
        upper Limit
        4.0
        value
        3.0
denoms
  1. counts
    1. group Id
      OG000
      value
      299
    2. group Id
      OG001
      value
      305
    units
    Participants
description
PFS is defined as the time from randomization to the earlier of the dates of the first documentation of radiographic progressive disease or death due to any cause.
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants were randomized to receive 6.0 mg/kg of DS-1062a.
    id
    OG000
    title
    DS-1062a 6.0 mg/kg
  2. description
    Participants were randomized to receive 75 mg/m\^2 docetaxel.
    id
    OG001
    title
    Docetaxel 75 mg/m^2
param Type
MEDIAN
reporting Status
POSTED
time Frame
From randomization until disease progression or death (whichever occurs first), up to approximately 43 months
title
Progression-free Survival (PFS) As Assessed by Investigator Per RECIST v1.1 Following DS-1062a Versus Docetaxel
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice